We are making significant progress toward replenishing supply of the 0.25 mg, 0.5 mg and 1.0 mg doses for Wegovy™. While we do anticipate ongoing delays at the 1.7 mg dose, as well as the 2.4 mg maintenance dose throughout the remainder of the year, we remain on track to stabilize Wegovy™ supply in early 2022. However, people may continue to experience delays from time to time in filling prescriptions for Wegovy™ at local retail pharmacies. You can reach us at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday if you have questions or feedback – and select option 0 for more support. Read on for more details and please share any questions you may have. Thank you for your patience.

Since we made Wegovy™ available, there has been an unprecedented demand for this medicine, which led to the current supply shortage. To everyone affected, we want you to know we are doing all we can to make this right and that supporting you is our top priority. We will continue to provide up-to-date information on our progress toward restoring supply.

There are five doses of Wegovy™ – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg and 1.7 mg) until the fifth, maintenance dose (this full dose of 2.4 mg is intended for the fifth month of treatment and onwards.)

  • We have made significant progress in restoring the supply for the first three doses: 0.25 mg, 0.5 mg and 1.0 mg
  • We expect delays in the 1.7 mg dose, as well as the 2.4 mg maintenance dose to continue throughout the remainder of 2021

However, people may continue to experience delays from time to time in filling prescriptions for Wegovy™ at local retail pharmacies.

Our teams are working 24/7, however, making this medicine is a complex process that requires multiple steps and facilities, in both the United States and overseas. First, we produce the active ingredient in Wegovy™, which is then filled and assembled into the device it comes in. Finally, it’s packaged and sent out to a distribution center, and then to wholesalers who distribute to retail pharmacies nationwide.


Here are some of the recent steps we've taken to address the supply situation:

  • We have increased production. Our production teams continue to work seven days a week to restore supply
  • Our field teams are working closely with healthcare providers to keep them informed of supply updates
  • To better answer your questions, we have increased our communications to share up-to-date information about our progress toward restoring supply

We are here to help and ready to answer your questions at 1-888-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday – and select option 0 for more support.

If you have received Wegovy™, we expect that you will now likely be able to get your initial 0.25 mg starting dose prescription filled.

It is important to know and consider that you may experience disruptions in getting the 1.7 mg dose as well as the 2.4 mg maintenance dose throughout the remainder of the year.  

Please follow the dose escalation schedule in the Prescribing Information for Wegovy™. Importantly, the final decision as to whether and how you take this medication should be made together with your healthcare provider. For more information about the Wegovy™ dosing schedule, click here for the Prescribing Information and Medication Guide.

The staff at your local pharmacy are best suited to provide information about the availability of Wegovy™ at their store – at the starting 0.25 mg dose, as well as the subsequent four doses. We still recommend contacting them about your refills at least 1-2 weeks earlier than you normally would.

See a video from Dr. Jason Brett, executive director, medical affairs, obesity, Novo Nordisk Inc., who answers some of the key questions many of you have shared with us.

Wegovy™ is a prescription medicine indicated for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep it off used with a reduced-calorie meal plan and increased physical activity.

Please see below for important information, and don’t hesitate to call 1-833-4-WEGOVY (1-833-493-4689) and select option 0 for more support. You are our number one priority and we’re here to help.

Please click here for the Prescribing Information and Medication Guide.

Since increasing production, we have made significant progress to restore the supply of the 0.25 mg, 0.5 mg and 1.0 mg Wegovy™ doses. While we do anticipate ongoing delays at the 1.7 mg dose and 2.4 mg maintenance dose throughout the remainder of the year, we remain on track to stabilize Wegovy™ supply in early 2022. Thank you for your patience while we work to resolve this issue.

As you may know, there are five doses of Wegovy™ – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg and 1.7 mg) until the fifth, maintenance dose (2.4 mg). Although we have made progress in the availability of the 0.25 mg, 0.5 mg, and 1.0 mg doses, you may experience delays with the 1.7 mg dose and the 2.4 mg maintenance dose throughout the remainder of the year. We are on track to stabilize supply in early 2022.

Please work with your healthcare provider to determine the best approach to your overall weight management plan. For more information about the Wegovy™ dosing schedule, please visit: www.wegovy.com/about-wegovy/dosing-schedule.html.

We still recommend contacting your pharmacy about your refills at least 1-2 weeks earlier than you normally would. If you are unable to find a dose, we encourage you to speak to your healthcare provider about your treatment plan to determine the best course of action and options available to you. Your healthcare provider knows your past and current medical history best and they are most equipped to make clinical recommendations.

If you are interested in receiving more information about Wegovy™ please sign up at www.Wegovy.com.

Making this medicine is a complex process that requires multiple steps and facilities, both in the United States and overseas. First, we produce the active ingredient in Wegovy™, which is then filled and assembled into the device it comes in. Finally, it’s packaged and sent out to a distribution center, and then to wholesalers who distribute to retail pharmacies nationwide.

Thousands of pharmacies will carry Wegovy™ across the country as supply is replenished. Unfortunately, we don’t have access to which pharmacies will or won’t have Wegovy™ in stock, or where the best place to fill a Wegovy™ prescription would be nearest to you. Please contact your local pharmacy for information about their ability to obtain Wegovy™ at the dose you need.

You may continue to experience delays from time to time in filling prescriptions for Wegovy™ at local retail pharmacies.

Please follow the dose escalation schedule in the Prescribing Information for Wegovy™. Importantly, the final decision as to whether and how you take this medication should be made together with your healthcare provider.

For more information about the Wegovy™ dosing schedule, click here for the Prescribing Information and Medication Guide.

Although Wegovy™ and Ozempic® both contain semaglutide, they are different products with different indications, dosages, titration schedules, etc. The products are not interchangeable. Please speak with your healthcare provider to discuss your treatment options.

The amount that you will pay for Wegovy once the Limited-Time Savings offer ends depends on your insurance coverage. We recommend that you immediately find out if you have prescription coverage for Wegovy™. The savings offer was intended for healthcare providers to extend to those patients with insurance coverage for anti-obesity medicines who were awaiting Wegovy™ to potentially be added to their prescription plan. So please check whether Wegovy™ is covered by your plan and if not, know there may be other ways to gain coverage. To learn more, visit: https://www.novocare.com/wegovy/cost-navigator.html

Novo Nordisk continues to work within the current healthcare system to obtain broader coverage and greater access to anti-obesity therapies for people with obesity. We also advocate for policies that support access to the full continuum of obesity treatment, including anti-obesity medications. With persistence and science, we are driving change through education, public and private partnerships, and advocacy.

By working together, these efforts will lead to greater understanding of obesity as a chronic disease requiring a continuum of care, and result in improved access to care and improved health outcomes. We will continue to partner to drive change for people living with obesity.

Was this helpful?

Was this helpful?

Let us know! Please rate your experience with this page. *

{{crossValidationError['Was this page helpful'].crossValidationErrorMessage}}

If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.

Your Career Guide